U.S. hemophilia treatment market size is expected to reach US$ 6.92 Bn by 2032, from US$ 4.48 Bn in 2025, exhibiting a compound annual growth rate (CAGR) of 6.4% during the forecast period.
Hemophilia A is an inherited and serious disorder in which a person blood does not clot properly that leads to uncontrolled and often spontaneous bleeding. Hemophilia A affects around 900,000 people worldwide, approximately 35-39% of them has severe form of the Hemophilia disorder. People with hemophilia A either lacks or do not have enough clotting protein called factor VIII. In a healthy person, when a bleed occurs, factor VIII brings together the clotting factors IXa and X, this is a critical step in the formation of a blood clot to stop bleeding. Depending on the severity of disorder, people with hemophilia A can bleed frequently, especially into their joints or muscles. These bleeds causes health concern as it often cause pain, and can lead to chronic swelling, deformity, reduced mobility, and long-term joint damage.
Favorable reimbursement policies for hemophilia treatment in the country are encouraging patients to seek medical help. Continuous efforts by market players for developing advanced treatment options, such as extended half-life factor products, are providing opportunities for market expansion. However, high costs that are associated with hemophilia care pose a major challenge to widespread adoption of therapies. Stringent regulations for product approval also hinder the market growth to some extent.
U.S. Hemophilia Treatment Market Drivers:
U.S. Hemophilia Treatment Market Opportunities:
U.S. Hemophilia Treatment Market Restraints:
U.S.
hemophilia treatment market size is expected to reach US$ 6.92 Bn by 2032, from US$ 4.48 Bn in 2025, exhibiting a compound annual growth rate (CAGR) of 6.4% during the forecast period.
Hemophilia A is an inherited and serious disorder in which a person blood does not clot properly that leads to uncontrolled and often spontaneous bleeding.
Hemophilia A affects around 900,000 people worldwide, approximately 35-39% of them has severe form of the Hemophilia disorder.
People with hemophilia A either lacks or do not have enough clotting protein called factor VIII.
In a healthy person, when a bleed occurs, factor VIII brings together the clotting factors IXa and X, this is a critical step in the formation of a blood clot to stop bleeding.
Depending on the severity of disorder, people with hemophilia A can bleed frequently, especially into their joints or muscles.
These bleeds causes health concern as it often cause pain, and can lead to chronic swelling, deformity, reduced mobility, and long-term joint damage.
Favorable reimbursement policies for hemophilia treatment in the country are encouraging patients to seek medical help.
Continuous efforts by market players for developing advanced treatment options, such as extended half-life factor products, are providing opportunities for market expansion.
However, high costs that are associated with hemophilia care pose a major challenge to widespread adoption of therapies.
Stringent regulations for product approval also hinder the market growth to some extent.
Market Size in USD Bn
CAGR6.4%
Study Period | 2025-2032 |
Base Year of Estimation | 2024 |
CAGR | 6.4% |
Larget Market | Northeast |
Market Concentration | High |
Major Players | Takeda Pharmaceutical Company Limited, Sanofi Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc. and Among Others |
U.S. Hemophilia Treatment Market Regional Insights:
Major players operating in the U.S. hemophilia treatment market include Takeda Pharmaceutical Company Limited., Sanofi Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and Spark Therapeutics, Inc.
Major players operating in the U.S.
hemophilia treatment market include Takeda Pharmaceutical Company Limited., Sanofi Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and Spark Therapeutics, Inc.
New product launches:
Acquisition and partnerships:
Would you like to explore the option of buying individual sections of this report?
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars.
His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs.
He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities.
His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
U.S. Hemophilia Treatment Market is Segmented By Product Type (Recombinant Coagulation Factor, Plasm...
U.S. Hemophilia Treatment Market
How big is the U.S. Hemophilia Treatment Market?
The U.S. Hemophilia Treatment Market is estimated to be valued at USD 4.48 in 2025 and is expected to reach USD 6.92 Billion by 2032.
What are the major factors driving the U.S. hemophilia treatment market growth?
Increasing prevalence of hemophilia A and B and approval of novel therapies are major factors driving the U.S. hemophilia treatment market growth.
Which is the leading disease type segment in the U.S. hemophilia treatment market?
The leading disease type segment in the U.S. hemophilia treatment market is the hemophilia A.
Which are the major players operating in the U.S. hemophilia treatment market?
The major players operating in the U.S. hemophilia treatment market are Takeda Pharmaceutical Company Limited., Sanofi Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and Spark Therapeutics, Inc.
Which region will lead the U.S. hemophilia treatment market?
Northeast is expected to lead the U.S. hemophilia treatment market.
What will be the CAGR of U.S. hemophilia treatment market?
The CAGR of U.S. hemophilia treatment market is projected to be 6.4%.